Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127975001 | 12797500 | 1 | I | 20110315 | 20110607 | 20160930 | 20160930 | EXP | US-ROCHE-785760 | ROCHE | 68.70 | YR | F | Y | 0.00000 | 20160930 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127975001 | 12797500 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE: 28 DAYS; OVER 30-90 MIN ON DAYS 1 AND 15, DATE OF MOST RECENT DOSE: 04/MAR/2011 | Y | 125085 | 10 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127975001 | 12797500 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 859 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1588 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1594 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1588 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1584 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 7 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 844 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 8 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 1552 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 9 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | 125085 | 859 | MG | SOLUTION FOR INFUSION | |||||||
| 127975001 | 12797500 | 10 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE: 28 DAYS; ON DAY 1, 8, 15 AND 22, DATE OF MOST RECENT DOSE: 11/MAR/2011 | Y | 0 | 25 | MG | |||||||
| 127975001 | 12797500 | 11 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 75 | MG | ||||||||
| 127975001 | 12797500 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 100 | MG | ||||||||
| 127975001 | 12797500 | 13 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 100 | MG | ||||||||
| 127975001 | 12797500 | 14 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 75 | MG | ||||||||
| 127975001 | 12797500 | 15 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 100 | MG | ||||||||
| 127975001 | 12797500 | 16 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 50 | MG | ||||||||
| 127975001 | 12797500 | 17 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | 0 | 75 | MG | ||||||||
| 127975001 | 12797500 | 18 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Unknown | 0 | 300 | MG | TABLET | ||||||||
| 127975001 | 12797500 | 19 | C | AMBIEN | ZOLPIDEM TARTRATE | 1 | Unknown | 0 | 5 | MG | TABLET | ||||||||
| 127975001 | 12797500 | 20 | C | DOXYCYCLINE HYCLATE. | DOXYCYCLINE HYCLATE | 1 | Unknown | 0 | 100 | MG | CAPSULE | ||||||||
| 127975001 | 12797500 | 21 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | 0 | 37.5 | MG | QD | ||||||||
| 127975001 | 12797500 | 22 | C | K-DUR 20 | 2 | 0 | |||||||||||||
| 127975001 | 12797500 | 23 | C | LISINOPRIL. | LISINOPRIL | 1 | Unknown | 0 | 2.5 | MG | TABLET | ||||||||
| 127975001 | 12797500 | 24 | C | LYRICA | PREGABALIN | 1 | Unknown | 0 | 150 | MG | CAPSULE | ||||||||
| 127975001 | 12797500 | 25 | C | MS CONTIN | MORPHINE SULFATE | 1 | Unknown | 0 | 15 | MG | TABLET | ||||||||
| 127975001 | 12797500 | 26 | C | NORCO | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | 0 | ||||||||||||
| 127975001 | 12797500 | 27 | C | PHENERGAN | PROMETHAZINE HYDROCHLORIDE | 1 | Unknown | 0 | 25 | MG | |||||||||
| 127975001 | 12797500 | 28 | C | PROPRANOLOL | PROPRANOLOLPROPRANOLOL HYDROCHLORIDE | 1 | Unknown | 0 | 40 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127975001 | 12797500 | 1 | Neuroendocrine carcinoma |
| 127975001 | 12797500 | 10 | Neuroendocrine carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127975001 | 12797500 | HO |
| 127975001 | 12797500 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127975001 | 12797500 | Adverse drug reaction | |
| 127975001 | 12797500 | Blood alkaline phosphatase increased | |
| 127975001 | 12797500 | Blood bilirubin increased | |
| 127975001 | 12797500 | Dehydration | |
| 127975001 | 12797500 | Electrolyte imbalance | |
| 127975001 | 12797500 | Hypertension | |
| 127975001 | 12797500 | Hypokalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |